Genome-wide screening identifies unique host-directed drugs and pro-viral signalling pathways for SARS-CoV-2
Juveriya Qamar Khan, Karthic Rajamanickam, Frederick S. Vizeacoumar, Mahrokh Balouchi et autres
0 citationsnpj Viruses
Frederick S. Vizeacoumar
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
256Publications signalées
3203Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Monoclonal and Polyclonal Antibodies ResearchRadiopharmaceutical Chemistry and ApplicationsRNA and protein synthesis mechanismsNutrition, Genetics, and DiseaseEpigenetics and DNA Methylation
Publications récentes
Differential effects on tumor progression by APOBEC3A, APOBEC3B, and APOBEC3H Haplotype I in a breast cancer mouse xenograft model
Milaid Granadillo Rodríguez, Lai Wong, Arzhang Shayeganmehr, Diogo Pellegrina et autres
0 citationsFrontiers in Genetics
Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing
He Dong, Frederick S. Vizeacoumar, Yue Zhang, Nicholas Jette et autres
3 citationsbioRxiv (Cold Spring Harbor Laboratory)
Supplementary Materials and Methods1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Figure S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Figure S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Figure S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
Figure S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, Sara L. Banerjee et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.